MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Merck & Co. Depreciation & Amortization 2011-2026 | MRK
Annual Depreciation & Amortization Merck & Co.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.04 B | 2.1 B | 1.83 B | 1.82 B | 1.58 B | 1.67 B | 3.65 B | 4.52 B | 4.64 B | 5.44 B | 6.38 B | 6.69 B | 6.99 B | 6.98 B | 7.43 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.43 B | 1.58 B | 4.32 B |
Quarterly Depreciation & Amortization Merck & Co.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 502 M | - | - | 511 M | - | - | 448 M | - | 1.39 B | - | 421 M | - | 1.15 B | - | 378 M | - | 1.21 B | 808 M | 821 M | - | 2.72 B | 1.87 B | 898 M | - | 3.52 B | 2.43 B | 1.14 B | - | 3.51 B | 2.36 B | 1.19 B | - | 4.29 B | 3.11 B | 1.56 B | - | 4.82 B | 3.24 B | 1.64 B | - | 5.12 B | 3.51 B | 1.75 B | - | 5.03 B | 3.33 B | 1.67 B | - | 5.32 B | 3.59 B | 1.79 B | - | 5.57 B | 3.66 B | 1.83 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.57 B | 378 M | 2.38 B |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ACADIA Pharmaceuticals
ACAD
|
920 K | $ 22.56 | 2.13 % | $ 3.74 B |  USA |
 |
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | USA |
 |
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M |  China |
 |
Akebia Therapeutics
AKBA
|
1.27 M | $ 1.43 | 3.62 % | $ 368 M | USA |
 |
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
55.7 M | $ 327.25 | 2.42 % | $ 42.9 B | USA |
 |
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
8.3 M | $ 1.49 | 9.56 % | $ 397 M |  Britain |
 |
AVROBIO
AVRO
|
617 K | - | 1083.1 % | $ 745 M | USA |
 |
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
31.6 M | $ 20.4 | -0.87 % | $ 954 M | USA |
 |
Aquestive Therapeutics
AQST
|
548 K | $ 4.18 | 1.21 % | $ 447 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M |  Israel |
 |
Aytu BioScience
AYTU
|
5.38 M | $ 2.66 | 3.5 % | $ 16.7 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
199 K | - | -2.5 % | $ 5.88 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
700 K | $ 24.61 | 5.76 % | $ 3.13 B | USA |
 |
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M |  Canada |
 |
Checkmate Pharmaceuticals
CMPI
|
66 K | - | - | $ 231 M | USA |
 |
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | USA |
 |
Cabaletta Bio
CABA
|
1.65 M | $ 3.09 | 0.65 % | $ 310 M | USA |
 |
CymaBay Therapeutics
CBAY
|
681 K | - | - | $ 3.45 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | USA |
 |
Codiak BioSciences
CDAK
|
5.34 M | - | -55.98 % | $ 2.15 M | USA |
 |
Avid Bioservices
CDMO
|
11.1 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
154 K | - | - | $ 1.41 B | USA |
 |
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Celldex Therapeutics
CLDX
|
3.38 M | $ 32.41 | 3.38 % | $ 2.15 B | USA |
 |
Celsion Corporation
CLSN
|
292 K | - | -6.63 % | $ 13.9 M | USA |
 |
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | USA |
 |
Chimerix
CMRX
|
91 K | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
1.48 M | - | - | $ 401 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
14 K | $ 3.88 | 2.11 % | $ 261 B | Britain |